ECACC New Accessions in 2025
In 2025, 11 new cell lines were added to the ECACC collection. The focus has been on providing drug resistant variants and clonal populations of already well-established cell lines within our collection. We also have some completely new cell lines too.
Derived from the parental line CHSE-214 (91041114), CHSE-E (20090901) is a genetically modified fish cell line that overexpresses a monomeric form of the Enhanced Green Fluorescent Protein (mEGFP) and is resistant to G418 (Geneticin) at a concentration of 500μg/ml. This cell line is susceptible to a multitude of fish viruses and, in many instances, replicates high titres.
In the field of ovarian cancer research, we have a new adriamycin resistant variant of OAW42 (85073102) named OAW42-A (20082613). Originally derived from the ascitic fluid of a patient with ovarian cystadenocarcinoma, OAW42 retains its ability to form free floating cysts and produces extracellular matrix. OAW42-A builds on these characteristics and is a valuable model for multidrug resistance as a result of its resistance to adriamycin for 3 months without drug exposure and cross resistance to Vincristine and Carboplatin.
Karpas 620 (22110802) is the latest human myeloma-related cell lines in the ECACC collection. The cultured cells have the ultrastructural appearance of plasma cells with abundant rough endoplasmic reticulum (RER) and secrete kappa light chain.
Deposits from the Dublin City University have allowed ECACC to provide multiple clonal derivatives of 2024's new cell line DLKP (20082601). These 3 derivatives show 3 morphologically distinct populations of the DLKP cell line. These different cell lines are DLKP-M (20082603) (mesenchymal like), DLKP-I (20022602) (intermediate) and DLKP-SQ (20082604) (squamous). The -SQ variant is the predominate population in the parental DLKP cell line (~70%) and forms large squamous-like cells which form colonies with distinct cell boundaries in monolayer culture. The -M variant is predominantly hyperdiploid and shows the most rapid attachment. The -I variant suggests increased therapeutic resistance due to 36% of its population being hypertetraploid.
In addition to these clonal variants, our collection boasts a range of adriamycin resistant variants of DLKP. Starting with DLKP-A (20082607) which exhibits adriamycin resistance to 2.45µg/ml and ending with DLKP-A10 (20082609) which is resistant to adriamycin at 10µg/ml.
SK MES 1 (93120837), derived from the pleural effusion of a patient with squamous cell carcinoma of the lung has a new adriamycin resistant variant available named SKMES-1-Adr (20082611). The cell line SKMES-1-Adr was created to measure the uptake and efflux of adriamycin, in which to examine the effects of inhibitors of multidrug resistance.
We are in the process of accessioning different drug-resistant variants of these lines and these will be on the Culture Collections website soon.
We also have a new hybridoma for 2025. ImmunoBiology Ltd have developed a mouse hybridoma, 1G2F8 (21043001), that produces an antibody which targets the antigen DnaK on Streptococcus pneumonia. DnaK supports Streptococcus pneumonia’s cell survival under stress, promoting homeostasis and preserving cell viability. The 1G2F8 antibody (confirmed as IgG1) has been used in ELISA to detect Pneumococcal surface protein A (PspA) and shows potential for use in diagnostic and vaccine research.